Q3 EPS Forecast for Prelude Therapeutics Boosted by Analyst

Prelude Therapeutics Incorporated (NASDAQ:PRLD) – Investment analysts at HC Wainwright raised their Q3 2026 earnings estimates for Prelude Therapeutics in a research note issued to investors on Tuesday, October 13th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.13) for the quarter, up from their prior estimate of ($0.16). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Prelude Therapeutics’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Prelude Therapeutics’ Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.54) EPS and FY2027 earnings at ($0.67) EPS.

PRLD has been the topic of a number of other reports. Wall Street Zen lowered Prelude Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, September 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prelude Therapeutics in a report on Wednesday, July 29th. JPMorgan Chase & Co. initiated coverage on Prelude Therapeutics in a research report on Thursday, September 17th. They issued an “overweight” rating and a $12.00 price target for the company. Finally, Citigroup reiterated a “market outperform” rating on shares of Prelude Therapeutics in a research report on Wednesday. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.75.

Prelude Therapeutics Stock Performance

Shares of NASDAQ:PRLD opened at $3.32 on Friday. The company has a market capitalization of $264.94 million, a PE ratio of -4.55 and a beta of 0.97. The stock has a fifty day moving average of $4.86 and a 200-day moving average of $4.53. Prelude Therapeutics has a one year low of $1.16 and a one year high of $6.83.

Prelude Therapeutics (NASDAQ:PRLD) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.06. The business had revenue of $5.70 million during the quarter, compared to analyst estimates of $5.70 million.

Institutional Investors Weigh In On Prelude Therapeutics

A number of large investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Prelude Therapeutics in the 2nd quarter valued at approximately $9,581,000. EcoR1 Capital LLC purchased a new position in Prelude Therapeutics during the 1st quarter worth approximately $3,239,000. ADAR1 Capital Management LLC purchased a new position in Prelude Therapeutics during the 2nd quarter worth approximately $4,802,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Prelude Therapeutics during the 2nd quarter valued at $669,000. Finally, Bank of New York Mellon Corp acquired a new stake in Prelude Therapeutics during the 2nd quarter valued at $363,000. Institutional investors and hedge funds own 79.72% of the company’s stock.

Prelude Therapeutics Company Profile

Prelude Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company uses cancer biology, medicinal chemistry and targeted drug-discovery approaches to identify small-molecule therapies designed to address genetic and molecular vulnerabilities in tumors.

Prelude’s investigational pipeline has included PRT3789, a selective SMARCA2 protein degrader being developed for cancers with SMARCA4 loss, and PRT2527, a selective cyclin-dependent kinase 9 (CDK9) inhibitor under evaluation for oncology applications.